Document is current
Any future updates will be listed below
-
Authors
Franzoi, Maria Alice
Santolaya, Carlota
Martin, Elise
Fasse, Leonor
Rouby, Pascal
Minot-This, Marie Sophie
Di Meglio, Antonio
Vaz-Luis, Ines
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (ASCO CDA)
Maison des Sciences de l’Homme Paris (INTERTOX, INTERTOX)
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 6 May 2025
First Online: 12 June 2025
Declarations
:
: Maria Alice Franzoi: Research funding: Resilience Care (Institution); Gilead Sciences (Institution), Speaker Honoraria: Novartis. Antonio Di Meglio: Consulting fees: Kephren, Medycis, EpiPhare, Techspert. Ines Vaz-Luis: Speaker honoraria from Amgen, AstraZeneca, Pfizer/Edimark, Novartis, Sandoz (Institutional); Writing engagement from Pfizer/Edimark (Institutional); Research funding from Resilience Care (Institutional), Travelling Novartis. Leonor Fasse: speaker honoraria from Lilly and MSD; research funding from AMGEN (institutional). Elise Martin, Carlota Santolaya, and Pascal Rouby report no conflict of interests.
: Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology or Conquer Cancer, or Breast Cancer Research Foundation. Elise Martin and Maria Alice Franzoi had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Presented in part as a poster at the 2024 MASCC Annual Meeting (Poster Discussion).
